WaveMan
WaveMan · Company
BCAX · Bicara Therapeutics Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BCAX Bicara Therapeutics (BCAX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0002023658
Quote by TradingView
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
108
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $501.0K priced

What the filings say about BCAX

Insiders, 180 days
-$4.2M net sold
3 sellers · 11% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.3M
6 notices

Bicara Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Bicara Therapeutics Inc. insiders sold a net $4.2M of stock across 80 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Cohlhepp Ryan
President, COO & Interim CEO
SELL
2026-09-10 SECtraded 2026-09-08
14,058
$320.1K
-26.0%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Aug 10, 2026.
  • The trade is 7.6% of the 185,083 shares held after it.
  • 2 other insiders sold within 30 days.
  • 108 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, COO & Interim CEO Cohlhepp Ryan sold about $320.1K of BCAX under a 10b5-1 plan on Sep 8, 2026; 2 other insiders sold within 30 days and 108 funds added in the latest 13F quarter.
Cohlhepp Ryan
President, COO & Interim CEO
SELL
2026-09-10 SECtraded 2026-09-08
3,442
$80.7K
-26.0%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Aug 10, 2026.
  • The trade is 1.9% of the 181,641 shares held after it.
  • 2 other insiders sold within 30 days.
  • 108 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, COO & Interim CEO Cohlhepp Ryan sold about $80.7K of BCAX under a 10b5-1 plan on Sep 8, 2026; 2 other insiders sold within 30 days and 108 funds added in the latest 13F quarter.
Hyep Ivan
Chief Financial Officer
SELL
2026-08-12 SECtraded 2026-08-10
12,500
$349.6K
-28.5%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Jul 8, 2026.
  • The trade is 9.6% of the 129,855 shares held after it.
  • 2 other insiders sold within 30 days.
  • 108 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Hyep Ivan sold about $349.6K of BCAX on Aug 10, 2026; 2 other insiders sold within 30 days and 108 funds added in the latest 13F quarter.
Mazumdar Claire
Chief Executive Officer
SELL
2026-08-12 SECtraded 2026-08-10
10,000
$279.8K
-28.5%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Jul 10, 2026.
  • The trade is 2.8% of the 362,152 shares held after it.
  • 2 other insiders sold within 30 days.
  • 108 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Mazumdar Claire sold about $279.8K of BCAX on Aug 10, 2026; 2 other insiders sold within 30 days and 108 funds added in the latest 13F quarter.
Cohlhepp Ryan
President and COO
SELL
2026-08-12 SECtraded 2026-08-10
18,750
$524.5K
-28.5%
Context
  • 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Jul 9, 2026.
  • The trade is 10.3% of the 181,641 shares held after it.
  • 2 other insiders sold within 30 days.
  • 108 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO Cohlhepp Ryan sold about $524.5K of BCAX on Aug 10, 2026; 2 other insiders sold within 30 days and 108 funds added in the latest 13F quarter.
80 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 75 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.2M over 180 days
-$1.6M over 90 days
below 77% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
108 funds bought in last quarter
more than 72% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
29.0% of the float short (float per yahoo 2026-10-26) · 14.2 days to cover · settled 2026-09-30
more than 88% of Pharma & Biotech
What changed in the last 30 days
Oct 21Officer DAVID RABEN filed to sell $449.0K by Oct 21 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch BCAX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+2.7%12M
-15%+18%+51%+85%2025-102025-122026-022026-042026-062026-082026-10 2026-02-26 · RA CAPITAL MANAGEMENT, L.P. bought $4.8M2025-11-24 · Mazumdar Claire sold $776.3K2026-03-09 · Mazumdar Claire sold $704.8K2026-07-08 · Cohlhepp Ryan sold $656.7K2026-07-08 · Hyep Ivan sold $650.9K2026-08-10 · Cohlhepp Ryan sold $524.5K2026-04-20 · Mazumdar Claire sold $354.1K2026-08-10 · Hyep Ivan sold $349.6K2025-11-24 · Hyep Ivan sold $330.1K2026-09-08 · Cohlhepp Ryan sold $320.1K2026-03-04 · Raben David sold $301.9K2026-07-10 · Mazumdar Claire sold $283.4K2026-08-10 · Mazumdar Claire sold $279.8K2026-03-03 · Hyep Ivan sold $247.0K2026-05-18 · Mazumdar Claire sold $240.0K2026-03-03 · Cohlhepp Ryan sold $234.1K2026-04-21 · Hyep Ivan sold $211.6K2026-05-21 · Hyep Ivan sold $187.9K2026-04-15 · Cohlhepp Ryan sold $184.1K2026-03-23 · Hyep Ivan sold $170.4K2025-12-22 · Hyep Ivan sold $168.5K2026-05-15 · Cohlhepp Ryan sold $162.3K2026-03-16 · Cohlhepp Ryan sold $157.3K2025-12-15 · Cohlhepp Ryan sold $149.4K2025-11-21 · Cohlhepp Ryan sold $144.4K2026-07-08 · Hyep Ivan sold $131.6K2026-03-19 · Mazumdar Claire sold $129.7K2026-07-08 · Cohlhepp Ryan sold $128.3K2026-04-27 · Raben David sold $125.8K2026-03-18 · Mazumdar Claire sold $122.4K2026-03-25 · Raben David sold $104.2K2026-04-15 · Cohlhepp Ryan sold $103.5K2025-11-24 · Raben David sold $101.5K2026-05-15 · Cohlhepp Ryan sold $91.3K2026-03-16 · Cohlhepp Ryan sold $88.5K2025-11-25 · Raben David sold $86.6K2025-12-15 · Cohlhepp Ryan sold $84.1K2026-03-03 · Cohlhepp Ryan sold $81.7K2025-11-21 · Cohlhepp Ryan sold $81.2K2026-09-08 · Cohlhepp Ryan sold $80.7K2026-03-06 · Mazumdar Claire sold $71.6K2026-01-22 · Cohlhepp Ryan sold $69.3K2026-10-21 · DAVID RABEN filed to sell $449.0K2026-09-08 · Cohlhepp Ryan filed to sell $396.2K2026-09-08 · Hyep Ivan filed to sell $283.0K2026-08-10 · Mazumdar Claire filed to sell $278.3K2026-08-10 · Cohlhepp Ryan filed to sell $521.8K2026-08-10 · Hyep Ivan filed to sell $347.9K2026-07-10 · Mazumdar Claire filed to sell $296.8K2026-07-08 · DAVID RABEN filed to sell $1.4M2026-07-08 · Hyep Ivan filed to sell $847.0K2026-07-08 · Cohlhepp Ryan filed to sell $869.7K2026-07-07 · Lara Meisner filed to sell $29.8K2026-06-25 · DAVID RABEN filed to sell $1.3M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BCAX: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
7,255,993 sh
$215.4M
Siren, L.L.C.
5,602,970 sh
$166.4M
Vestal Point Capital, LP
5,250,000 sh
$155.9M
Deep Track Capital, LP
4,100,000 sh
$121.7M
BlackRock, Inc.
3,848,090 sh
$114.2M

Congress trades in BCAX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BCAX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
DAVID RABEN
Filed 2026-10-21
$449.0K
Cohlhepp Ryan
Filed 2026-09-08
$396.2K
Hyep Ivan
Filed 2026-09-08
$283.0K
Mazumdar Claire
Filed 2026-08-10
$278.3K
Cohlhepp Ryan
Filed 2026-08-10
$521.8K

BCAX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
CapForce IBD Breakout Opportunities ETF
$1.1M position · as of 2026-07-31
7.0%
Franklin Biotechnology Discovery Fund
$12.9M position · as of 2026-07-31
1.1%
ALPS Medical Breakthroughs ETF
$1.4M position · as of 2026-05-31
0.9%
Virtus Biotech Clinical Trials Etf
$388.4K position · as of 2026-07-31
0.8%
ClearBridge Small Cap Fund
$5.7M position · as of 2026-07-31
0.8%
T. Rowe Price Small-Cap Stock Fund, Inc.
$64.7M position · as of 2026-06-30
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Phase 2
1 active
1
Multi-phase
1 active
What changed recently
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Pat
2026-10-07 · Completion moved 2026-12-31 → 2027-10-31
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.2M sold by insiders over 180 days, 108 funds added last quarter, $2.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BCAX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$135.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-41.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-38.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-44.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-12.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$155.6M-$82.4M-$39.9M
Net income-$137.9M-$68.0M-$52.0M
EPS (diluted)n/an/an/a
Operating cash flow-$106.8M-$74.8M-$45.6M
Cash$96.7M$489.7M$230.4M
SEC XBRL, fiscal years, as known on 2026-10-27

BCAX Stock Sonar score 4/7 axes

Find similar shapesCompare

BCAX ranks highest on institutional and government (72nd percentile) and profitability (56th), and lowest on risk and compliance (5th), among Pharma & Biotech peers.

Profitability
56
Inputs
  • Return on equity-41.0% · 59 pct, sector of 545
  • Return on assets-38.4% · 54 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-44.6% · 55 pct, sector of 576
Insider conviction
11
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.8M · 21 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
72
Inputs
  • Funds adding, latest quarter108 · 72 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
5
Inputs
  • Short interest, % of float+29.0% · 5 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BCAX filings, in plain words

Are Bicara Therapeutics insiders buying or selling BCAX?

In the 180 days to 2026-10-27, Bicara Therapeutics insiders were net sellers, a net $4.2M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of BCAX?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $2.3M of stock; the latest, by DAVID RABEN, was filed 2026-10-21.

Read the full summary

In the 180 days to 2026-10-27, Bicara Therapeutics insiders were net sellers of BCAX, a net $4.2M across purchases and sales reported on Form 4 by 3 sellers. 11% of the 19 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $2.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies